Literature DB >> 17978603

Reducing cardiovascular events in high-risk patients: the challenge of managing hypertension in patients with diabetic renal disease.

Robert D Toto1.   

Abstract

Hypertension is more prevalent and more difficult to control and is associated with a higher mortality rate in patients with diabetes than in nondiabetic patients. Elevated blood pressure contributes importantly to the development of albuminuria and progression of renal damage in diabetic nephropathy. Strong evidence indicates that the presence of albuminuria and overt nephropathy in patients with type 1 and type 2 diabetes is associated with a marked increase in the rate of fatal and nonfatal cardiovascular events. Blockade of the renin-angiotensin system in patients with type 2 diabetes with or without chronic kidney disease is associated with a significant reduction in risk for cardiovascular events. Renin-angiotensin system-blocking agents should be considered first-step pharmacologic therapy for hypertension in diabetic patients, with addition of other agents, if needed, to meet the recommended blood pressure goal of <130/80 mm Hg. In most instances, a diuretic is also needed to reduce blood pressure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17978603      PMCID: PMC8109917          DOI: 10.1111/j.1524-6175.2007.07723.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  83 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Authors:  J F Mann; H C Gerstein; J Pogue; J Bosch; S Yusuf
Journal:  Ann Intern Med       Date:  2001-04-17       Impact factor: 25.391

3.  Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy.

Authors:  K J Schjoedt; K Rossing; T R Juhl; F Boomsma; L Tarnow; P Rossing; H-H Parving
Journal:  Kidney Int       Date:  2006-06-14       Impact factor: 10.612

4.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals.

Authors:  H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf
Journal:  JAMA       Date:  2001-07-25       Impact factor: 56.272

Review 5.  Nephropathy in type 2 diabetes.

Authors:  E Ritz
Journal:  J Intern Med       Date:  1999-02       Impact factor: 8.989

6.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

7.  Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide.

Authors:  Steven G Chrysant; Michael A Weber; Antonia C Wang; Donald J Hinman
Journal:  Am J Hypertens       Date:  2004-03       Impact factor: 2.689

Review 8.  Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease.

Authors:  Bertram Pitt; Charles T Stier; Sanjay Rajagopalan
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2003-09       Impact factor: 1.636

9.  Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy.

Authors:  Dick de Zeeuw; Giuseppe Remuzzi; Hans-Henrik Parving; William F Keane; Zhongxin Zhang; Shahnaz Shahinfar; Steve Snapinn; Mark E Cooper; William E Mitch; Barry M Brenner
Journal:  Circulation       Date:  2004-08-09       Impact factor: 29.690

10.  Chronic kidney disease and cardiovascular disease in the Medicare population.

Authors:  Allan J Collins; Shuling Li; David T Gilbertson; Jiannong Liu; Shu-Cheng Chen; Charles A Herzog
Journal:  Kidney Int Suppl       Date:  2003-11       Impact factor: 10.545

View more
  1 in total

Review 1.  [Hypertension and the kidney].

Authors:  Katharina Hohenstein; Bruno Watschinger
Journal:  Wien Med Wochenschr       Date:  2008
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.